In English
NIDA

NIDA Notes Articles: Medication Development

NIDA Notes Category Graphic

Naltrexone Implant Outperforms Daily Pill in Russian Trial

noviembre del 2013

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

NIDA Notes Category Graphic

Naltrexone via Skin Patch Proves Effectiveness of New Technology

noviembre del 2009

Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.

NIDA Notes Category Graphic

Naltrexone-Nicotine Patch Combination Shows Promise

abril del 2007
Reports findings from a clinical trial investigating the effectiveness of naltrexone as a supplement to nicotine replacement therapy for smoking cessation.

NIDA Notes Category Graphic

Neuropeptide Promotes Behaviors Tied to Addiction and Overeating

julio del 2011

Reports on several studies implicating a certain neuropeptide (a signaling molecule) in fostering addition and overeating and discusses implications for addiction treatment.

NIDA Notes Category Graphic

New Tools and Strategies to Bolster Behavioral Therapy

octubre del 2010

Reports on research investigating whether certain medications might strengthen patients' understanding and memory retention.

NIDA Notes Category Graphic

New Vaccines Are Being Developed Against Addiction and Relapse

diciembre del 2008

Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.

NIDA Notes Category Graphic

NIDA Announces Avant-Garde Medication Development Awards

Marzo del 2012
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.

NIDA Notes Category Graphic

NIDA Appoints New Director of the Intramural Research Program

diciembre del 2010
Announces NIDA’s new director of its intramural research program, Antonello Bonci, M.D., a leading researcher in neuropsychopharmacology.

NIDA Notes Category Graphic

Oxycodone Vaccine Passes Early Tests

mayo del 2013

A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.

NIDA Notes Category Graphic

Potential Pain Medication Targets Peripheral Nerves

septiembre del 2012

Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.

Páginas

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics

Toma el reto nacional sobre el coeficiente intelectual (CI) sobre las drogas